Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): Impressions from MONET (the motesanib NSCLC efficacy and tolerability study)

Daniel Morgensztern, Roy S. Herbst

Research output: Contribution to journalEditorial

4 Scopus citations
Original languageEnglish
Pages (from-to)2805-2808
Number of pages4
JournalJournal of Clinical Oncology
Issue number23
StatePublished - Aug 24 2012

Cite this